Covance dials up revenue but dims its full-year outlook

Covance ($CVD) posted a strong revenue performance in the second quarter thanks to better-than-expected results from its early-stage development segment, but the CRO is inching back its full-year expectations to account for some outgoing assets.

The company netted $639 million on the quarter, an 8.1% jump over the same period last year. Covance's early-stage business grew 7.7% to $231.2 million due to an unexpected increase in demand for toxicology and pharmaceutical chemistry services, the CRO said, while its late-phase segment ticked up 8.1% to $408.3 million on strong sales for central laboratories that made up for a slump in clinical development.

But a spike in costs and expenses curtailed Covance's profits, which fell nearly 60% to $16.9 million on the quarter. The company reported a $52.6 million non-cash charge related to the closure of an animal testing facility in Arizona and another $4.2 million bill tied to ongoing restructuring.

Now Covance is slightly dimming its expectations for the year, reducing its best-case revenue scenario by about $30 million to roughly $2.8 billion, or 8% annual growth.

But the CRO believes it's quarterly commercial performance is paving the way for a strong year. Covance reported net orders of $773 million in the second quarter, an 8.9% sequential increase that makes for a 1.21 book-to-bill ratio, the company said.

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.